Annals of internal medicine
-
Comment Randomized Controlled Trial
In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo.
Roubille F, Bouabdallaoui N, Kouz S, et al. Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. 2024;47:467-470. 38181203.
-
In the United States, costs of antidiabetes medications exceed $327 billion. ⋯ American College of Physicians. (PROSPERO: CRD42022382315).
-
Comment Randomized Controlled Trial
In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status.
Kosiborod MN, Verma S, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation. 2024;149:204-216. 37952180.